Anagliptin

Drug Profile

Anagliptin

Alternative Names: Beskoa; CWP-0403; SK-0403; Suiny

Latest Information Update: 02 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyowa Hakko; Sanwa Kagaku Kenkyusho
  • Developer JW Pharmaceutical; Kowa Pharmaceutical; Sanwa Kagaku Kenkyusho
  • Class Antihyperglycaemics; Nitriles; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors; Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 30 Sep 2015 Sanwa Kagaku Kenkyusho and Kowa Company complete a phase III trial for Type-2 diabetes mellitus in Japan (PO) (JapicCTI-132246)
  • 30 Jun 2015 Phase-II development is ongoing in USA and European Union
  • 30 Jun 2015 Phase-III development is ongoing in Asia (South Korea)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top